AMBEV S.A. current report, Q4 FY2017

Business Context and Reporting Period

This Form 6-K filing by AMBEV S.A. covers the month of September 2017, with the report filed on October 10, 2017. The document serves as a disclosure of securities and derivatives transactions involving the company's Board of Directors, Management, and related persons, in compliance with Article 11 of CVM Instruction # 358/2002.

Key Financial Metrics

The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details insider trading activity.

Group Transaction Type Securities Quantity Total Volume (R$)
Board of Directors Buy Call Options (ABEVI2 ON) 30,000 60,990.00
Board of Directors Sell Common Shares 12,775 268,978.83
Board of Directors Final Balance Common Shares 5,543,923 -
Board of Directors Final Balance ADR Common 336,300 -
Management Activity None 0 0.00
Management Final Balance Common Shares 7,225 -

Material Changes

For the Board of Directors, the net change in common share holdings was a reduction of 12,775 shares. The group also acquired 30,000 call options (ABEVI2 ON) during the period. The Management group reported no transactions, maintaining a static balance of 7,225 common shares.

Guidance, Outlook, and Risks

The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of insider trading positions and transactions.

Investor Verification Checklist

  • Verify the specific identities of the Board members who executed the 12,775 share sales and 30,000 option purchases.
  • Confirm the strike price and expiration date of the ABEVI2 ON call options purchased by the Board.
  • Review the company's broader 20-F or 40-F filings for actual financial performance metrics, as this 6-K contains none.
  • Check if the sold shares were part of a pre-arranged trading plan (Rule 10b5-1 equivalent) or discretionary sales.